PMV Pharmaceuticals Inc. (PMVP)
PMV Pharmaceuticals Inc. (PMVP) Stock Price, Analysis & Data
| Bid | 0.94 |
| Market Cap | 67.2M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -78.34M |
| Beta | 1.35 |
| EPS (ttm) | -1.42 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.15 |
| P/B (ttm) | 0.76 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 13, 2026 |
| Ask | 1.63 |
| Volume | 208,252 |
| Avg. Volume (20D) | 328,161 |
| Open | 1.30 |
| Previous Close | 1.30 |
| Day's Range | 1.25 - 1.32 |
| 52-Week Range | 1.02 - 1.88 |
| Analyst | n/a |
| Price Target | 4 (217.46%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PMVP
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in ...
Financial Performance
In 2025, PMV Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -77.74M, an increase of 32.42%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for PMVP stock is "null". The 12-month stock price forecast is 4, which is upside of 217.46% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
